Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648778 | Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg | PHASE1 | COMPLETED | 53 | — | — | Jan 1, 2003 | Feb 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Loxapine Succinate Capsules 25 mg |
| 2 | ACTIVE_COMPARATOR | Loxitane® Capsules 25 mg |
| Name | Type | Description |
|---|---|---|
| Loxapine Succinate Capsules 25 mg | DRUG | 25mg, single dose fasting |
| Loxitane® Capsules 25 mg | DRUG | 25mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female a. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. A...